• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)

    2/14/24 4:21:51 PM ET
    $AGLE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGLE alert in real time by email
    SC 13G/A 1 tm242424d8_sc13ga.htm SC 13G/A

     

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Spyre Therapeutics, Inc. (f/k/a Aeglea Biotherapeutics, Inc.)

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    00773J202**

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x    Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **On November 28, 2023 the Common Stock of Aeglea Biotherapeutics, Inc. commenced trading under the name Spyre Therapeutics, Inc. (the “Issuer”) with a CUSIP number of 00773J202.

     

     

     

     

     

    CUSIP No.  00773J202

     

     

    1

     

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors LP

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER

     

    -0-

     

    6

     

    SHARED VOTING POWER

     

    -0-

     

    7

     

    SOLE DISPOSITIVE POWER

     

    -0-

     

    8

     

    SHARED DISPOSITIVE POWER

     

    -0-

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    -0-

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

    ¨

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.0%

     

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

    IA, PN 

     

     

     

     

    CUSIP No.  00773J202

     

     

    1

     

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors (GP) LLC

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER

     

    -0-

     

    6

     

    SHARED VOTING POWER

     

    -0-

     

    7

     

    SOLE DISPOSITIVE POWER

     

    -0-

     

    8

     

    SHARED DISPOSITIVE POWER

     

    -0-

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    -0-

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

    ¨

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.0%

     

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

    HC, OO

     

     

     

     

    CUSIP No.  00773J202

     

     

    1

     

    NAMES OF REPORTING PERSONS

     

    Felix J. Baker

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER

     

    -0-

     

    6

     

    SHARED VOTING POWER

     

    -0-

     

    7

     

    SOLE DISPOSITIVE POWER

     

    -0-

     

    8

     

    SHARED DISPOSITIVE POWER

     

    -0-

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    -0-

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

    ¨

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.0%

     

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

    IN, HC

     

     

     

     

    CUSIP No.  00773J202

     

     

    1

     

    NAMES OF REPORTING PERSONS

     

    Julian C. Baker

     

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

     

    SEC USE ONLY

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

     

    SOLE VOTING POWER

     

    -0-

     

    6

     

    SHARED VOTING POWER

     

    -0-

     

    7

     

    SOLE DISPOSITIVE POWER

     

    -0-

     

    8

     

    SHARED DISPOSITIVE POWER

     

    -0-

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    -0-

     

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

     

    ¨

     

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.0%

     

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

    IN, HC

     

     

     

     

    Amendment No. 1 to Schedule 13G

     

    This Amendment No. 1 to Schedule 13G amends and restates the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a) Name of Issuer:

     

    Spyre Therapeutics, Inc.

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    221 Crescent Street, Building 23, Suite 105

     

    Waltham, MA 02453

     

    Item 2(a) Name of Person Filing:

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c) Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, $0.0001 par value per share (“Common Stock”)

     

    Item 2(e) CUSIP Number:

     

    00773J202

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

      (a)  ¨ Broker or dealer registered under Section 15 of the Exchange Act.
       
      (b)  ¨ Bank as defined in section 3(a)(6) of the Exchange Act.
       
      (c)  ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.
       
      (d)  ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

     

     

     

      (e)  x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
       
      (f)  ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
       
      (g)  x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
       
      (h)  ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
      (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
       
      (j)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. The Reporting Persons no longer beneficially own any securities of the Issuer.

     

    Name  Number of Shares   Percent of
    Class 
    Outstanding
     
    667, L.P.   0    0.0%
    Baker Brothers Life Sciences, L.P.   0    0.0%
    Total   0    0.0%

     

    Pursuant to the management agreements, as amended, among the Adviser, 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Funds”) and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities previously held by the Funds, and thus the Adviser had complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to have been beneficial owners of securities of the Issuer directly held by the Funds.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

     

     

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024 

     

      BAKER BROS. ADVISORS LP
       
      By: Baker Bros. Advisors (GP) LLC, its general partner
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

        /s/ Julian C. Baker
        Julian C. Baker
       
        /s/ Felix J. Baker
        Felix J. Baker

     

     

     

    Get the next $AGLE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGLE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AGLE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

      Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies for IBD patients, including half-life extended antibodies targeting α4β7 (SPY001) and TL1A (SPY002), which are both on track to enter clinical studies in 2024 $205 million of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with

      11/27/23 8:30:00 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Announces Grants of Inducement Awards

      WALTHAM, Mass., Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The inducement awards were approved on November 20, 20

      11/22/23 5:00:00 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Announces Grants of Inducement Awards

      WALTHAM, Mass., Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 2,900,000 shares of common stock of Aeglea to two non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on October 2, 2023 and were material to each employee's

      10/2/23 6:02:00 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGLE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mckenna Mark C.

      4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

      2/5/24 5:29:40 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Mckenna Mark C.

      3 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

      2/5/24 5:25:26 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Turtle Cameron

      4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

      2/2/24 8:31:10 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGLE
    SEC Filings

    See more
    • SEC Form 424B3 filed by Aeglea BioTherapeutics Inc.

      424B3 - Spyre Therapeutics, Inc. (0001636282) (Filer)

      2/6/24 9:37:09 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

      2/5/24 7:36:02 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

      1/18/24 4:26:28 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGLE
    Financials

    Live finance-specific insights

    See more
    • Aeglea BioTherapeutics Announces Grant of Inducement Awards

      AUSTIN, Texas and WALTHAM, Mass., June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the independent members of Aeglea's Board of Directors approved the grant of stock options to new employees (including the new members of management) as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan. The stock options were approved on June 21, 2023 and were material to each employee's acceptance of employment with Aeglea, in accordance with Nasdaq Listing Rule 5635(c)(4). Cameron Turtle, the Chief Operating Officer of Aegl

      6/23/23 4:30:00 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

      AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment with pegzilarginase (p <0.0001). Importantly, pronounced and sustained plasma arginine reduction was accompanied by a positive trend in Gross Motor Function Measure Part E (GMFM-E), a key clinical assessment of

      12/6/21 6:30:00 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency

      AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). Investors and the public are invited to listen to a live audio webcast of the conference call on December 6, 2021, at 8:00am ET, which can be accessed prior to the start of the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (In

      12/5/21 6:00:00 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGLE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

      Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies for IBD patients, including half-life extended antibodies targeting α4β7 (SPY001) and TL1A (SPY002), which are both on track to enter clinical studies in 2024 $205 million of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with

      11/27/23 8:30:00 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors

      AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to its board of directors. Mr. Smith currently serves as the chief financial officer of Rhythm Pharmaceuticals. "We are excited to welcome Hunter to our board of directors and to the Aeglea family," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Hunter brings a wealth of experience as a biotech leader including corporate strategy, global commercial planning and product

      11/16/21 7:01:00 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

      AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights. "2021 is proving to be a pivotal year for Aeglea. In the second quarter, we achieved a significant milestone in our second clinical development program. With the initiation of dosing in our Phase 1/2 clinical trial of AGLE-177, Aeglea is making progress for patients who suffer from Homocystinuria, a rare and progressive d

      8/5/21 8:30:00 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGLE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)

      SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

      2/14/24 8:47:14 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)

      SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

      2/14/24 4:51:41 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)

      SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

      2/14/24 4:37:08 PM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care